FDA Panel Backs Heart Failure Warning for AstraZeneca, Takeda Diabetes Drugs

A U.S. FDA advisory committee said that AstraZeneca's diabetes drug Onglyza and Takeda Pharmaceutical's rival product Nesina should carry information about the risk of heart failure.